Bio-arbitration

01Overview and value chain#

Markers EC: none — general patent/commercial arbitration law | OECD: bio-pharma, cross-cutting | Regulator: FDA (USA)

Bio-arbitration resolves patent, licensing, and commercial disputes between biotech and biopharmaceutical companies through arbitration and litigation rather than court trial, often involving settlements in the hundreds of millions to billions of dollars — a single 2026 settlement between Moderna and Arbutus/Genevant over mRNA lipid-nanoparticle patent rights closed at $2.25 billion. Unlike a dedicated “bio-arbitration” vendor category, this work is handled by the general intellectual-property litigation practices of a small number of elite law firms, for whom biotech patent disputes are one client vertical among several rather than a standalone specialty. As of 2026 only one firm was confirmed with strong, on-topic, own-domain evidence of an active biotech-specific arbitration/litigation practice; several other named candidates returned only weak or off-topic evidence, consistent with a field that is real but concentrated rather than a broad commercial vendor market.

The key directions of bio-arbitration are:

1. Patent settlement negotiation and litigation: representing a biotech or biopharma client through the full litigation-to-settlement cycle in a patent-infringement dispute, often running in parallel across multiple jurisdictions.
2. Licensing and royalty dispute resolution: resolving disputes over the terms, scope, or breach of a technology-licensing agreement between biotech partners.
3. International arbitration under institutional rules: disputes routed through bodies such as the ICC or AAA-ICDR rather than national courts, common in cross-border biotech partnerships.
4. Trade-secret and inventorship disputes: resolving disputes over who invented a given technology or whether confidential biotech know-how was misappropriated.

Sectoral value chain#

[Dispute arises] ──> [Pre-filing strategy] ──> [Litigation/arbitration filing] ──> [Discovery/evidence]
                                                          │
                                                (settlement negotiation)
                                                          │
                                                          ▼
[Resolution/settlement] <─── [Hearing/trial] <───────────┘

Value chain levels#

Cross-cutting technologies of the sector:

• Patent-portfolio analytics: tools for mapping the scope and validity risk of a biotech patent portfolio ahead of litigation.
• Technical expert coordination: managing the scientific expert testimony that is central to any biotech patent dispute.
• Cross-border enforcement mechanisms: the legal infrastructure for enforcing a settlement or award across multiple jurisdictions, common given biotech’s globally distributed manufacturing and licensing.

02US#

The US is the only region with a confirmed dedicated firm, reflecting the concentration of major biopharma patent litigation in a small number of elite US IP practices.

Biotech patent litigation and arbitration, elite IP practice#

• Morrison Foerster (MoFo): represented a party in the 2026 $2.25 billion global patent settlement between Moderna and Arbutus/Genevant over mRNA lipid-nanoparticle delivery technology, confirmed via the firm’s own news page and independent legal-press coverage of the settlement — a genuine, high-value, on-topic biotech patent dispute resolution.

03CN#

No Chinese firm with a dedicated, confirmed biotech-arbitration practice was found on a live screen. This is consistent with the broader pattern for this category — biotech patent disputes of this scale are concentrated in a small number of firms globally, and this article found no confirmed Chinese counterpart.

General IP litigation practice, no confirmed dedicated vendor#

• Market context: China’s growing biotech patent portfolio is a plausible future source of bio-arbitration activity, but this article found no Chinese firm with confirmed, on-topic evidence of a dedicated biotech-arbitration practice.
• Reopen condition: if a Chinese firm with a confirmed biotech-specific arbitration/litigation practice surfaces on a future screen, this section should be revised and the firm added to the table.

04EU#

No EU firm with a dedicated, confirmed biotech-arbitration practice was found on a live screen at the same confirmation strength as the US anchor firm. Institutional arbitration bodies (ICC, WIPO Arbitration Center) are active in the EU, but this article found no confirmed EU law firm with a dedicated biotech-arbitration practice comparable to Morrison Foerster’s confirmed US evidence.

Institutional arbitration infrastructure, no confirmed dedicated vendor#

• Market context: EU-based institutional arbitration bodies handle biotech disputes as part of a broader commercial-arbitration caseload, but this article found no confirmed EU firm with a dedicated, named biotech-arbitration practice.
• Reopen condition: if an EU firm with a confirmed biotech-specific arbitration practice surfaces on a future screen, this section should be revised and the firm added to the table.

05Leading companies and research institutes#

06Tech stack and innovations#

The category’s “technology” is primarily legal and analytical rather than a physical product — the tools that support a high-value biotech patent dispute rather than a marketed system.

1. Patent-portfolio and validity analysis:
   • Before filing, counsel maps the scope and validity risk of the relevant patent portfolio, a technical exercise requiring both legal and scientific expertise specific to the biotechnology at issue (in the Moderna-Arbutus case, mRNA lipid-nanoparticle delivery technology).
2. Multi-jurisdictional case coordination:
   • Major biotech patent disputes frequently run in parallel across multiple jurisdictions, requiring coordination between local counsel and the lead firm managing overall strategy.
3. Settlement structuring:
   • The $2.25 billion Moderna-Arbutus/Genevant settlement reflects the scale of value at stake in biotech IP disputes and the negotiation and structuring expertise required to resolve them without a full trial.

07Value chains and production pipelines#

Industrial pipeline of a biotech patent dispute resolution (US federal court / institutional arbitration)#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Dispute identification   │ ───> │ 2. Pre-filing strategy     │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Discovery/evidence       │ <─── │ 3. Filing                 │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Hearing/trial            │ ───> │ 6. Resolution/settlement   │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Dispute identification

A patent, licensing, or trade-secret conflict is identified between biotech parties, often surfacing through a cease-and-desist letter or a competing product launch.

Stage 2: Pre-filing strategy

Counsel assesses the forum (court vs. arbitration), relevant jurisdictions, and the underlying settlement leverage before any filing.

Stage 3: Filing

The dispute is formally filed in the chosen forum, initiating the formal legal process.

Stage 4: Discovery/evidence

Both parties exchange technical evidence and expert analysis relevant to the biotechnology at the center of the dispute.

Stage 5: Hearing/trial

The dispute is argued before a judge, jury, or arbitration panel if it does not settle beforehand.

Stage 6: Resolution/settlement

The parties reach a negotiated settlement, as in the $2.25 billion Moderna-Arbutus/Genevant case, or the tribunal issues a final binding award.